Next-Generation Oncology Delivered by RNA Nanostructures
Multi-payload delivery (3+) with staggered intracellular release of drugs, led by our therapy for metastatic colon cancer
Modern therapy is shifting toward a 'systems engineering' approach. It’s about the orchestration of multiple agents within a single delivery event—using staged release to ensure that the primary payload primes the target before the secondary payload delivers the finishing blow."
Dr.. Robert Langer-MIT
“The study shows that 4-way junction RNA nanoparticles remain structurally intact in circulation, enter cells efficiently, and deliver their therapeutic cargo through natural cellular pathways—supporting safer, more precise drug delivery with reduced off-target effects.”
Wang H. et al. Chemical Engineering Journal 526 (2025)
About RNA Nanobiotics
Engineering the future of cancer therapeutics
RNA NanoBiotics is engineering a new class of targeted therapeutics designed to overcome the limitations of conventional drug delivery in difficult-to-treat cancers. The lead program delivers an approved chemotherapeutic payload directly to metastatic colorectal cancer cells, improving tumor specificity while reducing systemic toxicity. Leveraging a 505(b)(2) regulatory pathway, the company is positioned to accelerate clinical entry. Built on peer-reviewed science, issued patents, and validated in multiple preclinical models, the platform is modular and adaptable, enabling expansion across additional oncology indications following initial clinical validation.
RNA NanoBiotics Team
James J Carroll, MBA
Dr Krystle Karoscik, PhD
Dr Krystle Karoscik, PhD
President, CEO and Chairman
25+ years in Executive Management, strategy, corporate and business development, and investments. President of Wharton Alumni Angels
Wharton
Dr Krystle Karoscik, PhD
Dr Krystle Karoscik, PhD
Dr Krystle Karoscik, PhD
Chief Technology Officer
Technology, Operations and Strategy Executive, Niche in Translational Research and Clinical & Commercial Strategy, Serial entrepreneur in therapeutics and med-tech, Led >20 early-stage clinical programs, Managing Director of Life Sciences, Wharton Alumni Angels, VP BoD Penn Club of Boston; Co-Chair of Women in Lead
Chief Technology Officer
Technology, Operations and Strategy Executive, Niche in Translational Research and Clinical & Commercial Strategy, Serial entrepreneur in therapeutics and med-tech, Led >20 early-stage clinical programs, Managing Director of Life Sciences, Wharton Alumni Angels, VP BoD Penn Club of Boston; Co-Chair of Women in Leadership fostering development in STEM and finance
Penn
Dr. Peixuan Guo
Dr Krystle Karoscik, PhD
Dr Ildiko Csiki, MD. PhD
Chairman Scientific Advisory Board
Professor, Sylvan G. Frank Endowed Chair
Pharmaceutics and Pharmacology, Ohio State University; 2021 Innovator Of The Year Ohio State University; Fellow of the National Academy of Inventors (NAI); Director of Center for RNA Nanobiotechnology and Nanomedicine; President of International Society of RNA Nanot
Chairman Scientific Advisory Board
Professor, Sylvan G. Frank Endowed Chair
Pharmaceutics and Pharmacology, Ohio State University; 2021 Innovator Of The Year Ohio State University; Fellow of the National Academy of Inventors (NAI); Director of Center for RNA Nanobiotechnology and Nanomedicine; President of International Society of RNA Nanotechnology and Nanomedicine; International Society of RNA Nanotechnology and Nanomedicine
Dr Ildiko Csiki, MD. PhD
Dr Ildiko Csiki, MD. PhD
Dr Ildiko Csiki, MD. PhD
Board Member
Pioneered strategic initiatives in drug development, leading to significant advancements in cancer treatment and patient care. Spearheaded the development and commercialization of groundbreaking therapies, overseeing research, business development, and licensing. Expert in clinical trial design.
Wharton
Dr Cynthia Cai, PhD, MBA
Dr Ildiko Csiki, MD. PhD
Dr Cynthia Cai, PhD, MBA
Board Member
Executive & Investor with 25+ years in healthcare and life sciences, experienced in equity investment, board governance, marketing, and business development; Board Member of Spectral AI (NASDAQ: MDAI), Arthrosi Therapeutics, Amberstone Biosciences, Basking Biosciences, HAYA Therapeutics, and the Science History Institute.
Wharton.